Welcome and Introduction
Reducing Cardiovascular Risk in Type 2 Diabetes: What I Do and Why
A series of case patients illustrating concepts and issues with diabetes treatment
Case 1: New Onset T2DM in the Older Patients
- Cardiometabolic syndrome/CV risk factors
- Patient factors and A1C goals
- Glycemic control and CV risk
Case 2: Established T2DM and Stroke
- Hypoglycemia, cerebrovascular disease
- Implications for patients with moderate CV risk
Case 3: Established T2DM and Coronary Artery Disease
- Treatment options: CV safety data, clinical study data
- Implications for patients with moderate-to-high CV risk
Case 4: Established T2DM and Heart Failure
- Treatment options: CV safety data, clinical study data, and real-world evidence
- Implications for patients with high CV risk
Closing Remarks and Audience Question and Answer Session
Date / Time
Hyatt Regency Orlando
Zachary Bloomgarden, MD, MACE
Division of Endocrinology
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Mikhail Kosiborod, MD, FACC, FAHA
Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
Kansas City, Missouri
Pamela Kushner, MD, FAAFP
University of California Irvine Medical Center
Los Alamitos, California
In this highly interactive program, a panel of expert faculty members will walk you through their individual approaches to selecting appropriate type 2 diabetes mellitus therapy based on clinical trial results and real-world evidence evaluating the impact of therapies on CV risk.
The goal of this activity is to improve participants’ competence in applying treatment strategies that leverage new and emerging antihyperglycemic therapies in the management of patients with T2DM and elevated CV risk.
This program is intended for endocrinologists, internists, primary care physicians, physician assistants, nurse practitioners, nurses, and other healthcare providers who care for patients with T2DM and CV risk factors.
- Routinely assess patients with T2DM for CV risk factors based on an understanding of the pathophysiology of cardiometabolic syndrome
- Consider the recent CV outcomes data from pivotal trials of antihyperglycemics when making treatment decisions for patients with poor glycemic control and established CV disease
- Weigh real-world evidence for CV risk reduction of antihyperglycemics in patients with varying degrees of CV risk to help determine therapy selection in the setting of low to medium CV risk
Physician Continuing Medical Education
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.